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Signiﬁcant progress in our understanding of risk factors and interventions in heart failure, a leading
cause of death and disability, has occurred in recent years. Several advances in therapy for heart failure
with reduced left ventricular systolic function (i.e., systolic heart failure) have led to signiﬁcantly
improved outcomes. Treatment options for diastolic heart failure, also known as heart failure with
preserved ejection fraction (HFpEF), by contrast, remain comparatively limited. In part, this is due to gaps
in our understanding of the underlying pathophysiology and the lack of standardized criteria for its
diagnosis and classiﬁcation. Aging and hypertension remain the leading causes of HFpEF; increased
ventricular and vascular stiffness is a feature of both. Comorbidities such as diabetes, renal insufﬁciency,
and metabolic abnormalities further aggravate disease process, and data regarding effective treatment
are lacking. This article discusses the risks, mechanisms, and outcomes of HFpEF from previous studies,
and summarizes potential interventions that may provide new insights into our understanding of the
disease and its treatment.
Copyright  2013, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Heart failure (HF), a clinical syndrome associated with poor
clinical outcomes, has traditionally been considered to be systolic
HF with dilated ventricular volume and reduced systolic con-
tractility and characterized as a reduction in ventricular ejection
fraction1e3. This syndrome, which becomes more prevalent with
age, affects almost 2% of western populations4. More recently,
however, it has become clear that HF commonly exists in the midst
of preserved ventricular systolic function5e7. This HF with pre-
served ejection fraction (HFpEF) affects 50% of all HF patients
based on population-based studies8. Although the data on HFpEF
are sometimes inconsistent and conﬂicting, patients classiﬁed asterest.
artment of Medicine, Mackay
Road, Sanzhi District, New
iwan Society of Geriatric EmergenHFpEF share common clinical features and similarly grave prog-
nosis as those with reduced systolic function8,9. In earlier studies,
HFpEF prevalence varied from 13% to 74%10, with recent reports of
a prevalence of 40e71%, or an average of 54% of the HF population11
(Fig. 1). The lack of diagnostic standardization, misdiagnosis, and
existence of comorbidities or deconditioning were among factors
contributing to the underlying inherent selection bias12. Addition-
ally, differing sample inclusion criteria from recent large
community-based samples in the USA (including the Olmsted
Heart Study13, Cardiovascular Health Study14, and Strong Heart
Study15) and some other European countries (including the UK16,
The Netherlands17, Sweden18, Portugal19, and Finland20) were
contributory. Although there is a potential for misdiagnosis and
a lack of consensus for HfpEF, common clinical features do exist in
this heterogeneous patient population. The prevalence of HFpEF
increases with advancing age, female gender, and this is a con-
sistent trend across the whole HF population19. The true prevalence
of HFpEF in the community, however, may range from 1.1% to 5.5%
of the general population8.cy & Critical Care Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. The detailed percentage list of possible risks (including history of hypertension, diabetes, coronary artery disease, and atrial ﬁbrillation) for the development of heart failure
with preserved ejection fraction from various studies including registries, population-based studies, and controlled clinical trials. The black star denotes those data lacking in the
original studies.
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of the heart’s ability to eject or ﬁll sufﬁciently to match the meta-
bolic needs of whole body tissue perfusion, resulting in the classic
constellation of clinical symptoms and signs21. Our major focus in
this article is HFpEF, deﬁned as either impaired left ventricular (LV)
relaxation, diastolic suction, postsystolic recoil, or ﬁlling deﬁcit that
results in altered ventricular properties and persistent elevation in
LV end-diastolic pressure at rest or exacerbated during exercise22. A
comprehensive guideline for clinical diagnosis has been recently
developed by the Echocardiography and Heart Failure Associations
of the European Society of Cardiology23. The diagnostic criteria
adopted comprise three major features: (1) clinical signs and
symptoms of HF; (2) objective evidence of normal LV systolic
function; and (3) evidence of diastolic dysfunction. A diagnostic
ﬂowchart based on a composite of conventional two-dimensional
echocardiography, hemodynamic and tissue Doppler echocardiog-
raphy, biomarkers such as brain natriuretic peptide and N-terminal
pro-B-type natriuretic peptide (NT-ProBNP) have been developed
as a guide to a more precise and standardized deﬁnition of HFpEF.
As previously noted, the clinical outcomes related to HFpEF are
unfavorable, with an estimated annual mortality rate ranging from
3.5% to 6% in some of the large randomized clinical trials4e12,15.
There is some discrepancy about the real causes of death between
observational community-based studies20,24,25 and controlled
clinical trials26e29. The higher proportion of noncardiovascular
deaths in community-based studies may reﬂect the high comor-
bidity burden in real world patients when compared to those
enrolled in controlled clinical trials.
2. Risk factors and mechanisms of HFpEF
Various mechanisms including structural and functional
anomalies may play a role in the transition from asymptomatic
patients with established risk to HF development7,30e34. Diastolic
dysfunction (DD) plays a central role in the development of overt
HFpEF, although autonomic dysfunction35, neuro-hormonal acti-
vation36,37, and latent pulmonary hypertension38,39 need to beexcluded. Patients should also be evaluated for possible skeletal
muscle dysfunction or intrinsic muscle receptor abnormality as
potential causes of exertional dyspnea or fatigue40.
Several risk factors are associated with HFpEF. In contrast to SHF
or HF with reduced ejection fraction, HFpEF patients tend to be
elderly females with a history5 of hypertension8 compared to the
ischemic etiology that predominates in SHF. Fig. 1 summarizes the
data on risk factors from previous registries41e47 in population-
based cohorts8,9,15,48e51 and randomized studies26e28,52e55. In
addition, cardiovascular risk factors are also highly linked to HFpEF
in large-scaled studies; this includes obesity, diabetes, and hyper-
lipidemia44. Endothelial dysfunction may also contribute to this
process via alternate pathways56. In addition, a higher prevalence
of atrial ﬁbrillation was observed in patients with HFpEF, possibly
reﬂecting the loss of atrial function14,32,47.
While aging and hypertension remain the major risk factors for
HF development in epidemiological studies, phenotypic ventricular
structural changes such as maladaptive concentric remodeling,
most commonly accompanied by diastolic dysfunction57, are
believed to be the main substrate in HFpEF development58,59.
Functional assessment by evaluation of ventricular diastolic func-
tion may provide key insights into the transition from LV diastolic
dysfunction to overt clinical HF57e61.
Because cardiac function shares a strong physiologic interaction
with the rest of the vascular systemdthe ventricular-vascular
couplingdsimultaneous parallel functional decay may occur dur-
ing the pathologic processes resulting in HFpEF62,63. Concurrent
stiffening of both the systemic vasculature and themyocardium has
been observed, resulting from increased extracellular matrix
turnover, enhanced ﬁbroblastic activity, and progressive ﬁbrosis of
normal myocardiumdall crucial components in the observed
functional decay64,65. This altered ventriculo-arterial coupling and
stiffening typical of HFpEF is reﬂected in the steeper end-systolic
pressureevolume relationship. Compensatory myocardial hyper-
trophy and reduction in chamber-level shortening occur in
response to the persistent elevations in arterial pressures needed to
overcome elevated LV wall stress and arterial stiffness33,66.
Heart Failure with Preserved Ejection Fraction 33. Comorbidities involved and clinical scenarios mimicking
HFpEF
Diabetes may induce HFpEF through elevated resting tension
secondary to increased deposition of advanced glycation end
products and a ﬁbrotic myocardium67. Diabetic cardiomyopathy,
a clinical spectrum ranging from impaired cardiac function with
hypertrophied heart to overt dilated heart failure without obvious
coronary artery disease, can increase susceptibility and complicate
other clinical risks68. Renal dysfunction in terms of decreased glo-
merular ﬁltration rate, a common clinical condition concomitant
with worsening cardiac function in HF patients with or without
preserved EF, can further increasemortality69. Coexistingmetabolic
abnormalities further complicate the clinical course of HF, resulting
in a higher mortality rate.
Reduced exercise capacity and dyspnea raise the clinical suspi-
cion for HFpEF, although no deﬁnite cardiac structural or functional
abnormalities or minimal functional abnormalities can be ascri-
bed70. Skeletal muscle pathology, anemia71, pulmonary diseases72,
and deconditioned cardiopulmonary reserve, all need to be
explored12. Obesity itself can lead to exercise intolerance through
various mechanisms73,74. A clinical diagnostic challenge would be
evaluating a patient presenting with exercise limitation for HFpEF
who also has coexisting anemia, lung diseases, or obesity. All these
factors can contribute to the pathogenesis of, or at least seem to
share, clinical features in common with HFpEF through various
pathways.
4. Clinical diagnostic tools in HFpEF e from DD to subclinical
systolic dysfunction
DD, characterized by impaired ventricular ﬁlling including
decreased diastolic distensibility and impaired relaxation during
early diastolic phase, is thought to represent an important patho-
logical intermediate between hypertension and heart failure75,76.
DD is nowassociatedwith adverse clinical outcomes77. DD has been
observed in patients with minor alterations in ventricular geome-
try, but which nevertheless can contribute to worse clinical out-
comes78. At the cellular level, DD may be related to sarcomeric
dysfunction and increased extracellular matrix deposition30,79.
Regression of such ﬁbrosis of the myocardium can occur with
pharmacological intervention80. During the pathologic process,
derangements in sarcoplasmic reticulum-mediated calcium cycling
or sarcomeric thin ﬁlaments interaction may further impair dia-
stolic relaxation and systolic contraction81.
Characteristics of DD secondary to aging and hypertension may
be derived from noninvasive studies. However, invasive measures,
including pressureevolume curves used to assess ventricular ﬁlling
pressure, remain the gold standard for diagnosing HF82. End-
systolic elastance measured invasively may represent the degree
of ventricular ﬁlling and contractile abnormality in response to
arterial load at a speciﬁc end-systolic volume62. Isovolumic relax-
ation tau (s) is another invasive measure obtained by ﬁtting the
exponential curve to the pressure fall of left ventricle during dia-
stole and calculating the relaxation half-life23,83.
Hemodynamic indices assessed by transthoracic echocardiog-
raphy play a foundation role in the diagnosis of HFpEF23. How-
ever, tissue Doppler imaging (TDI) has emerged as a more robust,
less load-dependent measure84. The utility of mitral inﬂow
Doppler combined with TDI measures of diastolic function have
been validated by invasive studies85. Yu et al reported that lon-
gitudinal systolic myocardial contraction may begin to deteriorate
in HF patients even before chamber remodeling or dilatation86.
Noninvasive measures, in conjunction with serum biomarkers
such as BNP and NT-ProBNP, are included in the diagnosticcriteria for HFpEF in the European Society of Echocardiography
guidelines23.
New myocardial deformation imaging techniques based on
tissue Doppler or speckle-tracking permit more accurate quanti-
ﬁcation of global and regional myocardial function, and provides
useful information and new insights into cardiac mechanics
(Fig. 2)87,88. TDI-based techniques are angle-dependent and require
optimal parallel alignment to the interrogation beam; speckle-
tracking imaging (SIT) techniques are angle-independent.
SIT-based techniques facilitate the analysis of cardiac motion and
deformation independent of ultrasound beam direction, further
advancing our understanding of the mechanisms involved in
HFpEF88. Patients with HFpEF have impaired longitudinal and
radial function with preserved circumferential function and ven-
tricular twist as assessed by DTI and SIT techniques, thus giving
credence to the concept of subclinical systolic dysfunction. In
addition, studies using tissue velocity or deformation imaging by
magnetic resonance imaging or advanced echocardiography tech-
niques have demonstrated the coexistence of subclinical systolic
dysfunction and diastolic impairment in which myocardial energy
utilization deﬁcits existed86e88. Interestingly, those categorized as
HFpEF not only presented with less systolic and diastolic dys-
function at rest, but these abnormalities became more evident
during exercise, implying a simultaneous decrease in functional
reserve89.
5. Pharmacological interventions in HFpEF and related
studies
Several studies based on possible pharmacological interventions
for HFpEF have recently been conducted. The rationale may actually
involve the cessation of renineangiotensinealdosterone system
(RAAS), which may theoretically halt the progress of target organ
damage or myocardial ﬁbrosis leading to subsequent cardiac
chamber stiffness regression in terms of diastolic functional
improvement80. Vascular stiffening is linked to impaired ventric-
ular performance and has been shown to be the central factor of
aging and hypertension in the pathogenesis of HFpEF, hence,
calcium channel blockade aiming at relieving such disordered
coupling has been reported to improve exercise capacity in elderly
individuals90. Long-term treatment for hypertension is known to
result in hypertrophy regression, and RAAS inhibition may theo-
retically beneﬁt patients with heart failure and myocardial infarc-
tion beyond blood pressure lowering91.
The Valsartan in Diastolic Dysfunction (VALIDD) study, the only
randomized control enrollment research aiming at myocardial
functional improvement in hypertension patients, was conducted
to test the hypothesis that angiotensinogen-receptor blockade
(ARB) may be superior to alternative antihypertensive therapy76.
Both control and treatment arms had similar blood pressure
reduction regardless of themedication used, in addition to reaching
a similar increase in TDI deﬁned myocardial relaxation. The study
concluded that in the early stages of hypertension, the myocardial
functional improvement came from blood pressure control rather
than the medication used.
Some landmark pharmacological interventions related to HFpEF
with the associated results have been reported in several large trials
(Table 1)28,29,53. In the PEP-CHF study53, angiotensin-converting
enzyme inhibitor was introduced to elderly patients with HF
symptoms with preserved EF. After 2 years’ follow-up, the use of
Perindopril was associated with an increase in exercise capacity
and improvement of clinical symptoms. A trend toward decreased
heart failure hospitalizations and all-cause mortality was also
noted during the earlier stage (about 1 year), although the ﬁnal
result in the 3rd year did not show signiﬁcant differences.
Fig. 2. (AeD) A normal adult without heart failure (HF) and free from systemic diseases; (EeH) a case with hypertension, old stroke, renal insufﬁciency and HF symptoms. (A,E) Both
patients had normal left ventricular (LV) ejection fraction and preserved short-axis function without visible regional wall motion abnormality. Apical four-chamber view (B,F)
showing preserved LV function and tissue Doppler imaging (TDI) revealed preserved (C:11 cm/s) and severely impaired diastolic function (G: 4 cm/s), respectively. Bull’s-eye display
imaging by automatic functional imaging from all three apical axis (D) showed preserved global longitudinal strain (mean: 26.6%) and (H) decreased longitudinal global strain
(10.3%) indicating impaired global longitudinal systolic function in HF patient. (Figure produced and processed by Lo, Chi-In MD, Mackay Memorial Hospital Taipei, Taiwan.)
BMI ¼ body mass index.
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Table 1
Large clinical trials with pharmacological interventions related to heart failure with preserved ejection fraction.
Study
name




Duration Primary end-point Results
CHARM 200328 Candesartan T. groups (n ¼ 1514) 583 54 36.6 mo CV death or unplanned
Worsened HF hospitalization
Primary endpoint not met
(Preserved) (ARB) P. groups (n ¼ 1509) 604 54.1 (median) Reduced HF hospitalization
32 mg/day
Countries International
PEP-CHF 200653 Perindopril T. groups (n ¼ 424) 97 (23%) 65 2.1 y All cause death or
HF hospitalization
Improved symptoms and
6-min corridor walk distance
(ACEI) P. groups (n ¼ 426) 109 (26%) 64 (median) Reduced HF hospitalization at 1 y
4 mg/day
Countries Europe
I-PRESERVE 200829 Irbesartan T. groups (n ¼ 2067) 1641 (80%) 59 49.5 mo All cause death or
CV hospitalization
Primary Endpoint not met
(ARB) P. groups (n ¼ 2061) 1615 (79%) 60 (mean)
300 mg/day Countries International
Note. From Epidemiology and clinical course of heart failure with preserved ejection fraction, by C.S. Lam, E. Donal, E. Kraigher-Krainer, and R.S. Vasan 2010, Eur J Heart Fail. 13,
pp. 18e28. Copyright 2010, Oxford University Press/ on behalf of the Taiwan Society of Geriatric Emergency and Critical Care Medicine. Reprinted with permission.
ACEI¼ angiotensin-converting enzyme inhibitor; ARB¼ angiotensinogen-receptor blockade; CV¼ cardiovascular; Fc¼ functional class; HFpEF¼ heart failure with preserved
ejection fraction; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association; T. ¼ Treatment; G. ¼ Placebo.
Heart Failure with Preserved Ejection Fraction 5The Digitalis Investigation Group Congestive Heart Failure
(DIG-CHF) trial27 by Ahmed et al, an ancillary study with 988 pa-
tients, found that HF death and hospitalization tended to decrease
in the ﬁrst 2 years. At the end of this study (37 months later), this
beneﬁcial effect was not observed. One possible reason is that
a larger proportion in this study was composed of HF with ischemic
origin. Subsequently, a higher incidence of unstable angina with
hospitalization, which ﬁnally offset the borderline decrease of HF
related clinical events, was observed in the digoxin group.
The Candesartan in Heart failure: Assessment of. Reduction in
Mortality and morbidity (CHARM) study, a multicenter, interna-
tional randomized trial comparing the usage of ARB candesartan
added for optimal medical treatment in HF patients with and
without systolic dysfunction, revealed promising results28. This
large-scale study was the ﬁrst randomized trial associated with
HFpEF treatment, which underwent a median follow-up of 36
months. The clinical use of ARB in those with relatively preserved
LV systolic function (Preserved Arm) showed a trend of reduced
composite cardiovascular hospitalization and mortality, although
the statistically nonsigniﬁcant primary endpoint was met.
Another study, the Irbesartan in Heart Failure with Preserved
Systolic Function (I-PRESERVE) trial assessed the clinical use of ARB
irbesartan in patients with HF with preserved ejection fraction.
After an average of 4 years follow-up, again there were no signiﬁ-
cant differences in death from any cause and cardiovascular hos-
pitalizations29. The Treatment of Preserved Cardiac Function Heart
Failure with an Aldosterone Antagonist (TOPCAT) study is a double-
blinded, randomized, controlled trial with 150 US centers involved,
evaluating the effects of spironolactone (titrated up to 45 mg daily)
in patients with HFpEF (LV ejection fraction  45%) with primary
outcomes in cardiovascular death, cardiac arrest, and hospitaliza-
tions for heart failure92. Even though it is currently ongoing, the
results from this large trial may help to clarify whether potassium-
sparing diuretics would add additional beneﬁcial effects beyond
other proven pharmacological interventions in this patient
population.
So far, revascularization of heart failure patients using coronary
intervention does not seem to be a promising treatment modality.
The HEART study93, currently the largest randomized study of
revascularization for heart failure patients, failed to recruit the
original planned number of patients. At a median follow up of 5
years with a mean age of 67, the study failed to reveal an all-cause
mortality beneﬁt in these patients, but the lack of a conclusive
result may be underpowered by the obvious lack of a sufﬁcient
number of patients enrolled.6. Role of exercise intervention in HFpEF
Exercise training can improve vascular endothelial cell function
and efﬁciency of oxygen utilization of the peripheral muscle cell, as
well as decrease NT-ProBNP, vasopressin, aldosterone, and arterial
natriuretic peptide94,95. Potentially, exercise training can improve
exercise intolerance and increase exercise capacity in patients with
HFpEF. Even though it is well known that exercise training im-
proves diastolic function in healthy patients, the effect of exercise
intervention in HFpEF is still unclear based on current evidence.
Few studies have examined the effects of exercise training in pa-
tients with HFpEF. Yu et al found that patients with coronary artery
disease who had regular aerobic exercise training for 8 weeks, and
only the subgroup with an abnormal left ventricular relaxation
pattern revealed signiﬁcant improvement in DD96. Smart et al
investigated patients with DD, who had underwent a 16-week
aerobic exercise regimen with cycle ergometry 3 times/week, and
found a signiﬁcant 19% increase in exercise capacity and 30%
increase in peak oxygen uptake but without changes in diastolic
function97. However, in a more recent study [Exercise Training in
Tiastolic Heart Failure (Ex-DHF)], improvement of left ventricular
diastolic indices and atrial reverse remodeling were observed to
parallel the improvement of exercise capacity and peak O2 uptake
during a 3-month training interval in patients who presented with
HFpEF98. As a result, it is likely that the improvement of peripheral
mechanism may take place at the same time with diastolic
improvement, such as improvement of muscular aerobic metabo-
lism, increasemuscularmass or increase vasculature density, rather
than the increase of cardiac output that results in the gain in ex-
ercise capacity of patients with HFpEF leading to a better diastology
in such clinical scenarios40.
7. Summary
HFpEF as a clinical disease entity has gained much interest and
research attention in the coming era of aging population, HFpEF as
a clinical disease entity has gained much interest and research
attention in the coming era of aging population. While several
suggested imaging criteria or hints have been made in order to
improve the diagnostic accuracy and recognition of patients at risk
of clinical events in such population, there is limited consensus and
agreements based on current body of knowledge for daily practice
regarding this disease. Moreover, the lack of efﬁcient care delivery
in such population also urges more clinical works, either pharma-
cologic or physical approaches, on the conceptual development of
C.-L. Hung et al.6the exact pathological mechanisms underlying thus to help provide
effective treatment directions in the future.References
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